We are fascinated by the ability of tumors to evade immune elimination. Many of our current programs focus on restoring the power of the immune system to achieve clean tumor kills.
Tumors subvert immunity in a variety of ways. They can hide their very existence from innate cellular alarm systems and circulating surveillance immune cells, frustrate the buildup and amplification of immune responses and subvert established inflammatory responses by evoking potent immunosuppressive factors.
The recent approvals of inhibitors targeting checkpoint blockade are the first steps in the establishment of host directed immune therapies as durable methods for the treatment of a number of cancers. The coming decade will see the emergence of new generations of immune system targeted oncology drugs which can be used as monotherapy or in combination with other IO agents or existing anti-cancer drugs.